PEG-MGF
Research OnlyAlso known as: PEGylated Mechano Growth Factor, PEGylated MGF, IGF-1Ec PEG
A PEGylated form of Mechano Growth Factor (MGF), a splice variant of IGF-1 expressed in response to mechanical stress on muscle tissue. Named as one of five FDA Category 2 restricted peptides. Lacks clinical trial data despite popularity in fitness communities.
Research Statistics
Preclinical only. FDA Category 2 restricted. Fitness community interest exceeds evidence.
Research Dossier
Overview
What is PEG-MGF and what does the research say?
How It Works (Simplified)
PEG-MGF is a PEGylated (polyethylene glycol-modified) form of Mechano Growth Factor, a naturally occurring splice variant of IGF-1 (specifically the IGF-1Ec isoform). MGF is produced locally in muscle tissue in response to mechanical damage from exercise. The PEGylation extends the half-life from minutes to hours, allowing systemic administration. The compound is believed to activate muscle satellite cells, promoting muscle repair and hypertrophy.
Scientific Pathways
IGF-1 Splice Variant: MGF is produced by alternative splicing of the IGF-1 gene in response to mechanical stress. Unlike systemic IGF-1, MGF acts locally to activate satellite cells (muscle stem cells) and initiate repair.
PEGylation for Stability: Native MGF has an extremely short half-life (minutes) due to rapid degradation. PEGylation attaches polyethylene glycol chains to the peptide, extending its circulating half-life and enabling less frequent administration.
Satellite Cell Activation: Preclinical studies suggest MGF activates quiescent muscle satellite cells, promoting their proliferation and differentiation into myoblasts for muscle fiber repair and growth.
Clinical Evidence
Preclinical Data Only: Evidence for PEG-MGF is limited almost entirely to animal and cell culture studies. Mouse models show enhanced muscle repair following mechanical injury when MGF is administered. Cardiac studies in animal models suggest potential cardioprotective effects.
No Clinical Trials: No registered clinical trials (ClinicalTrials.gov) exist for PEG-MGF in any indication. The peptide has not undergone human safety or efficacy testing in a controlled setting. Any human use is unregulated and without clinical evidence support.
Safety Profile
Unknown in Humans: No human safety data from clinical trials exists. Theoretical concerns include: uncontrolled growth factor signaling (proliferative risk), potential for promoting existing malignancies through IGF-1 pathway activation, and unknown long-term effects of exogenous growth factor administration. The FDA’s Category 2 designation reflects these safety concerns.
Quality Concerns: As PEG-MGF is not manufactured under pharmaceutical GMP conditions, products available through research chemical suppliers may have purity, potency, and contamination issues.
Important Limitations
- FDA Category 2 restricted — not eligible for compounding
- No human clinical trials in any indication
- All efficacy data is preclinical (animal/cell studies only)
- Unknown human safety profile
- Quality and purity of available products unverified
- IGF-1 pathway activation carries theoretical oncological risk
- Fitness community claims vastly exceed available evidence
Peptide Interactions
Known and theoretical interactions when combining PEG-MGF with other peptides. Based on published research and mechanistic considerations.
Igf-1-Lr3
CautionBoth are IGF-1-related peptides. PEG-MGF is a splice variant while IGF-1 LR3 is the extended form. Overlapping growth factor signaling could increase proliferative risk.
MK-677
CautionMK-677 increases endogenous GH and IGF-1. Combining with exogenous PEG-MGF could lead to excessive growth factor stimulation.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare PEG-MGF
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
HMG
Human Menopausal Gonadotropin, Menotropins, hMG +4 more
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.